Q-omics provides the consensus-scored FRG2C profile across patient tissues and cancer cell-line models. FRG2C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FRG2C is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, FRG2C RNA expression shows 12,633 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KIRC, and THYM as cancer lineages where FRG2C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRG2C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRG2C survival associations across molecular data types. FRG2C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRG2C RNA expression–survival associations across cancer types. High FRG2C expression shows unfavorable associations in BLCA, SKCM and UVM, but favorable associations in UCS, HNSC and LIHC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .014). Together, the overview and detailed table identify UCS as the clearest survival context for FRG2C RNA expression.
This table summarizes FRG2C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FRG2C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRG2C shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in HNSC, LUSC and LUAD. The KIRC box plot shows higher FRG2C RNA expression in normal versus tumor tissue (log2 FC = −1.849, t-test p < 0.001).
This table shows molecular features associated with FRG2C in patient tissues and cancer cell lines. In patient samples, FRG2C shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FRG2C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
